Fulcrum Therapeutics announced the discontinuation of its sickle cell disease drug, pociredir, after the FDA raised serious safety concerns linked to a high rate of secondary blood cancers observed with a similar drug. This led to no viable regulatory path for further development, causing the company's stock to drop 51% in one day. Kaplan Fox & Kilsheimer LLP is now investigating potential securities violations related to this event, inviting affected investors to come forward. This development highlights significant regulatory risks in drug development for rare diseases and may impact investor confidence in the company.
The First Bancorp's shares have risen 30.6% since March, driven by improved fundamentals including a net interest margin increase to 2.88% and net profits of $9.6 million. Lower deposit costs and strong asset growth supported these gains. The stock t...
Curve DAO Token (CRV) surged over 16% in 24 hours, driven by rising demand in the DeFi sector for stablecoin liquidity to facilitate token swaps. Trading volume spiked 174% to $122 million, while active addresses and transactions on Curve Finance inc...
Hyperliquid Strategies has increased its equity purchase agreement ceiling to $2.5 billion, as per a September 1, 2026 SEC filing. This expansion allows the company greater access to capital through issuing new shares over time, enhancing its financi...
Target Hospitality Corp. reported a strong second quarter with revenue up 39% year-over-year and adjusted EBITDA increasing fivefold, driven by growth in its Workforce Housing Solutions segment. The company secured $1.4 billion in multi-year contract...
Cornerstone Robotics, a Hong Kong-based surgical robotics company, has secured a strategic partnership with Medtronic, which includes a $700 million investment. Medtronic gains distribution rights for Cornerstone's Sentire™ surgical system outside th...
